Gökhan AYTEKİN, Fatih ÇÖLKESEN, Eray YILDIZ, Şevket ARSLAN

Evaluation of the effectiveness of anti-IgE treatment in patients with chronic urticaria with an urticarial control test

Aim: Chronic spontaneous urticaria (CSU) is characterized by recurrent urticaria, angioedema and a combination of both over aperiod of more than 6 weeks. Anti-immunoglobulin E (IgE) monoclonal antibody (omalizumab) treatment is an effective and safetreatment modality that can be applied in antihistamine-resistant cases in patients with CSU and the urticaria control test is a simpleand useful test that evaluates the control level of the disease over the past 4 weeks.Material and Methods: Following appropriate urticaria control tests, 82 test results of 41 patients with CSU (23 females, 18 males)who received subcutaneous anti-IgE treatment at a dose of 300 mg/4 weeks for 6 months were evaluated retrospectively.Results: With each question, there was a statistically significant difference between the mean scores before treatment and at 6months of treatment (p: 0.001 for question 1, p: 0.001 for question 2, p: 0.001 for question 3, p: 0.001 for question 4). As a result,95.1% of the patients included in the study achieved a complete and/or partial response to treatment.Conclusion: Omalizumab treatment in patients with chronic spontaneous urticaria (CSU), is an effective and safe treatment modality,independent of the patients’ serum IgE levels, eosinophil counts, thyroid-stimulating hormone levels, C-reactive protein andsedimentation rates, presence or absence of anti-nuclear antibody (ANA) and regardless of whether angioedema is associated withchronic spontaneous urticaria. Furthermore, the urticaria control test is a practical test that can be used to evaluate the efficiencyof treatment in CSU patients

PDF

___

1. Zuberbier T, Aberer W, Asero R et al. The EAACI/ GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393-1414.
2. Goldsobel AB, Rohr AS, Siegel SC et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986;78:867-73.
3. Maurer M, Church MK, Marsland AM et al. Questions and answers in chronic urticaria: where do we stand and where do we go? J Eur Acad Dermatol Venereol 2016;30:7-15.
4. Maurer M, Abuzakouk M, Berard F et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy 2017;72:2005-16.
5. Greaves M. Chronic urticaria. The Journal of allergy and clinical immunology 2000;105:664-72.
6. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. Journal of investigational allergology & clinical immunology 2004;14:214-20.
7. Bernstein JA, Lang DM, Khan DA et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133:1270-7.
8. Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013;11:971-7.
9. Zuberbier T, Bernstein JA. A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines. J Allergy Clin Immunol Pract 2018;6:1144-51.
10. Godse K, De A, Zawar V et al. Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update. Indian journal of dermatology 2018;63:2-15.
11. Weller K, Groffik A, Church MK et al. Development and validation of the Urticaria Control Test: a patientreported outcome instrument for assessing urticaria control. The Journal of allergy and clinical immunology 2014;133:1365-76.
12. Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health and quality of life outcomes 2016;14:61.
13. Joint Task Force on Practice P. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2000;85:521-44.
14. Powell RJ, Du Toit GL, Siddique N et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2007;37:631-50.
15. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. The Journal of allergy and clinical immunology 2012;129:1307-13.
16. Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2009;103:496-501.
17. Turk M, Yilmaz I. Urticaria control test might misevaluate disease control in particular patients treated with omalizumab. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019;122:342-43.
18. Finlay AY, Kaplan AP, Beck LA et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology : JEADV 2017;31:1715-21.
19. Ghazanfar MN, Thomsen SF. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies. Case reports in medicine 2015;2015:368053.
20. Gimenez-Arnau AM, Spector S, Antonova E et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, doubleblind, placebo-controlled studies. Clinical and translational allergy 2016;6:32.
21. Kaplan A, Ledford D, Ashby M et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. The Journal of allergy and clinical immunology 2013;132:101-9.
22. Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017;72:519- 533.
23. Tharp MD, Bernstein JA, Kavati A et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of “Real-world” Evidence. JAMA dermatology 2018.
24. Zhao ZT, Ji CM, Yu WJ et al. Omalizumab for the treatment of chronic spontaneous urticaria: A metaanalysis of randomized clinical trials. The Journal of allergy and clinical immunology 2016;137:1742-50.
25. Kozel MM, Bossuyt PM, Mekkes JR, et al. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. Journal of the American Academy of Dermatology 2003;48:409-16.
26. Caffarelli C, Cuomo B, Cardinale F et al. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta dermato-venereologica 2013;93:268-72.
27. Chanprapaph K, Iamsumang W, Wattanakrai P, Vachiramon V. Thyroid Autoimmunity and Autoimmunity in Chronic Spontaneous Urticaria Linked to Disease Severity, Therapeutic Response, and Time to Remission in Patients with Chronic Spontaneous Urticaria. BioMed research international 2018;2018:9856843.
28. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Frontiers in immunology 2019;10:627.
29. Lazurova I, Benhatchi K, Rovensky J et al. Autoimmune thyroid disease and autoimmune rheumatic disorders: a two-sided analysis. Annals of the New York Academy of Sciences 2009;1173:211-6.
30. Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, et al. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Annals of the rheumatic diseases 2004;63:1159-61.
31. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. The New England journal of medicine 2002;346:175-9.
32. Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018;73:705-12.
33. Deza G, Bertolin-Colilla M, Pujol RM et al. Basophil FcepsilonRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. Acta dermatovenereologica 2017;97:698-704.
34. Zuberbier T, Aberer W, Asero R et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update, 2015.
35. Kaplan A, Ferrer M, Bernstein JA et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. The Journal of allergy and clinical immunology 2016;137:474-81.